• Medipost appointed Min Ho-sung as co-CEO and executive director on Oct. 29, 2026.
• The shift to an independent co-CEO structure aims to improve management expertise and efficiency.
• Min previously served as Samsung Biologics vice president from Sept. 4, 2023, to March 31, 2026.
• He was CEO of GenScript ProBio from April 1, 2019, to June 30, 2023.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medipost Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261029900785), on October 29, 2026, and is solely responsible for the information contained therein.